Non-Hodgkin Lymphoma Therapeutics Market Research Report 2020 Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Therapeutics</strong> <strong>Market</strong> <strong>Research</strong> <strong>Report</strong><br />
<strong>2020</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
GBI <strong>Research</strong>, the leading business intelligence provider, has released its latest research, '<strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong> <strong>Therapeutics</strong> in Asia-Pacific <strong>Market</strong>s to <strong>2020</strong> - Novel Technologies Show Considerable<br />
Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an<br />
estimation of market size for 2013 along with forecasts until <strong>2020</strong> for the Asia-Pacific (APAC) region,<br />
which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment<br />
algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline<br />
analysis, and analysis of deals relevant to <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> (NHL).<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a<br />
Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in <strong>2020</strong>. The expected launches of<br />
promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as<br />
well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers.<br />
The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors<br />
including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a<br />
significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance<br />
setting. An increasingly aging population and a year-on-year increase in the number of incident cases will<br />
provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in<br />
India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to<br />
generic dominance, especially in India, stand to curtail the APAC NHL market.<br />
Scope<br />
The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and<br />
co-development deals in the four APAC markets of Australia, China, India and Japan. It includes -<br />
- A brief introduction to NHL, including the disease's pathogenesis, etiology, diagnosis and treatment<br />
algorithms<br />
- In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment<br />
patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety<br />
and efficacy<br />
- A comprehensive review of the pipeline for NHL, including individual analysis of a number of latestage<br />
pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed<br />
on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and<br />
program failure rate for each molecule type<br />
- Multi-scenario forecast data of the market to <strong>2020</strong>, taking into account how the market may be affected<br />
by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease<br />
epidemiology across the key developed markets<br />
- Discussion of the drivers of and barriers to market growth<br />
- In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since<br />
2006<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
Reasons to buy<br />
The report will enhance your decision-making capability by allowing you to -<br />
- Understand the NHL pipeline and the factors that indicate that it is becoming more innovative<br />
- Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to<br />
compete in the market and who their main competitors will be<br />
- Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the<br />
potential risk of future developmental programs according to mechanism of action by considering the<br />
recorded clinical trial failure rates<br />
- Observe the potential growth patterns expected for the NHL market over the forecast period, identify<br />
which countries are expected to make the biggest contribution to this growth, and devise a more effective<br />
country - strategy through an understanding of key drivers and barriers in the NHL market<br />
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships<br />
Table of Contents<br />
Table of Contents 6<br />
1.1 List of Tables 8<br />
1.2 List of Figures 8<br />
2 Introduction 10<br />
2.1 Symptoms 10<br />
2.2 Etiology 11
2.3 Pathophysiology 11<br />
2.4 Diagnosis 12<br />
2.4.1 Biopsy 12<br />
2.4.2 Laboratory molecular tests 12<br />
2.4.3 Imaging tests 13<br />
2.5 Classification 13<br />
2.5.1 B-Cell lymphomas 14<br />
2.5.2 T-Cell <strong>Lymphoma</strong>s 16<br />
2.6 Epidemiology 17<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
2.7 Prognosis and Disease Staging 18<br />
2.7.1 Staging 19<br />
2.8 Treatment Options 20<br />
2.8.1 Surgery and Radiation Therapy 20<br />
2.8.2 Stem Cell Transplantation 20<br />
2.8.3 Pharmacological 20<br />
2.8.4 Treatment Algorithms and Prescribing Habits 22<br />
3 <strong>Market</strong>ed Products 24<br />
3.1 Therapeutic Landscape 24<br />
3.1.1 Immunotherapies 24<br />
3.1.2 Targeted Therapies 29<br />
3.1.3 Chemo-Regimens 32<br />
3.2 Comparative Efficacy and Safety (<strong>Market</strong>ed Products) 34<br />
4 Pipeline Products 37<br />
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 38<br />
4.3 Pipeline Analysis by Mechanism of Action 39<br />
4.4 Clinical Trials 41<br />
4.4.1 Failure Rate 41<br />
4.4.2 Patient Enrollment and Clinical Trial Size 42<br />
4.4.3 Duration 43<br />
4.5 Promising Drug Candidates in the Pipeline 44<br />
4.5.1 Idelalisib (GS-1101) - Gilead Sciences 44<br />
4.5.2 Imbruvica (Ibrutinib) - Pharmacyclics/Janssen Biotech 45<br />
4.5.3 Gazyva (Obinutuzumab) - Roche 45<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
4.5.4 Revlimid (lenalidomide) - Celgene 46<br />
4.5.5 Afinitor (everolimus) - Novartis 47<br />
4.6 Heat Map of Safety and Efficacy and Product Competitiveness Framework for <strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong> Pipeline 48<br />
5 <strong>Market</strong> Forecast to <strong>2020</strong> 51<br />
5.1 Geographical <strong>Market</strong>s 51<br />
5.1.1 APAC <strong>Market</strong> 51<br />
5.1.2 India 52<br />
5.1.3 Australia 55<br />
5.1.4 China 58<br />
5.1.5 Japan 60<br />
5.2 Drivers and Barriers for the Disease <strong>Market</strong> 63<br />
5.2.1 Drivers 63<br />
5.2.2 Barriers 64
6 Deals and Strategic Consolidations 65<br />
6.1 Major Co-development Deals 67<br />
6.1.1 Roche Signs an Agreement with GlycArt and Genentech 68<br />
6.1.2 Cell <strong>Therapeutics</strong> Enters Agreement with Bayer 68<br />
6.1.3 Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101 68<br />
6.1.4 GlaxoSmithKline Enters Co-development Agreement with Genmab 69<br />
6.1.5 Biogen Idec Enters Co-development Agreement with Genentech 69<br />
6.1.6 Seattle Genetics Enters Co-development Agreement with Millennium 69<br />
6.2 Major Licensing Deals 69<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
6.2.1 Spectrum Enters Licensing Agreement with Bayer for Zevalin 70<br />
6.2.2 Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765 70<br />
6.2.3 Lundbeck Enters Licensing Agreement with Cephalon 71<br />
6.2.4 TG <strong>Therapeutics</strong> Enters Licensing Agreement with Ildong for Ublituximab 71<br />
6.2.5 Provenance Enters Licensing Agreement with Merck Serono 71<br />
6.2.6 Cephalon Enters Licensing Agreement with SymBio 71<br />
6.2.7 Genentech Enters Licensing Agreement with Seattle Genetics 71<br />
7 Appendix 72<br />
7.1 <strong>Market</strong> Definitions 72<br />
7.2 Abbreviations 72<br />
7.3 Bibliography 75<br />
7.4 Pipeline Tables 78<br />
7.4.1 Discovery 78<br />
7.4.2 Preclinical 79<br />
7.4.3 Investigational New Drug-Filed 81
7.4.4 Phase I 82<br />
7.4.5 Phase II 85<br />
7.4.6 Phase III 89<br />
7.5 <strong>Market</strong> Forecasts to <strong>2020</strong> 90<br />
7.5.1 Asia-Pacific 90<br />
7.5.2 India 90<br />
7.5.3 Australia 91<br />
7.5.4 China 91<br />
7.5.5 Japan 92<br />
7.6 <strong>Research</strong> Methodology 92<br />
7.6.1 Coverage 92<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
7.6.2 Secondary <strong>Research</strong> 93<br />
7.6.3 Primary <strong>Research</strong> 93<br />
7.6.4 Therapeutic Landscape 93<br />
7.6.5 Geographical Landscape 95<br />
7.6.6 Pipeline Analysis 96<br />
7.7 Expert Panel Validation 96<br />
7.8 Contact Us 96<br />
7.9 Disclaimer 96<br />
List of Tables<br />
Table 1: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Therapeutics</strong>, Most Common Chromosomal Aberrations Associated<br />
With NHL 12<br />
Table 2: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Therapeutics</strong>, IWF Classification of Lymphoproliferative Diseases 14<br />
Table 3: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Classification of <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> 17
Table 4: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, IPI Good and Poor Prognostic Factors 18<br />
Table 5: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Ann Arbor Staging System for <strong>Lymphoma</strong> 19<br />
Table 6: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Commonly Used Chemo-Regimens 21<br />
Table 7: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Common Symptoms of <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> 26<br />
Table 8: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Endpoints of Various Chemotherapeutic Regimens (%) 33<br />
Table 9: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Efficacy Comparison of R-CHOP vs. CHOP 34<br />
Table 10: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Efficacy Comparison of CVP vs R-CVP 34<br />
Table 11: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Average Clinical Trial Duration (Months) 43<br />
Table 12: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Deals and Strategic Consolidations, 2006-2014 65<br />
Table 13: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Discovery), 2014 78<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
Table 14: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Preclinical), 2014 79<br />
Table 15: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (IND-filed), 2014 81<br />
Table 16: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Phase I), 2014 82<br />
Table 17: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Phase II), 2014 85<br />
Table 18: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Phase III), 2014 89<br />
Table 19: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Asia-Pacific, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 90<br />
Table 20: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 90<br />
Table 21: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Australia, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 91<br />
Table 22: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, China, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 91<br />
Table 23: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Japan, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 9<br />
List of Figures<br />
Figure 1: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Asia-Pacific, Distribution of Prevalence Population, 2013-<br />
<strong>2020</strong> 18
Figure 2: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Treatment Algorithm for Indolent <strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong>, 2014 22<br />
Figure 3: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Treatment Algorithm for Aggresive <strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong>, 2014 23<br />
Figure 4: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Rituxan, Annual Sales ($bn), 2006-2013 25<br />
Figure 5: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Adcetris, Annual Sales ($m), 2011-2013 27<br />
Figure 6: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Velcade, Annual Sales ($bn), 2007-2013 30<br />
Figure 7: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Istodax, Annual Sales ($m), 2010-2013 31<br />
Figure 8: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Comparative Safety and Efficacy of <strong>Market</strong>ed<br />
Products (Heat Map), 2014 36<br />
Figure 9: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline by Stage of Development, Program Type<br />
and Route of Administration, 2014 38<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
Figure 10: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline by Molecule Type and Stage of<br />
Development, 2014 39<br />
Figure 11: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline by Mechanism of Action, 2014 40<br />
Figure 12: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong>, Global, Pipeline by Mechanism of Action, Molecule Type and<br />
Stage of Development (Number), 2014 41<br />
Figure 13: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Clinical Trial Failure Rate (%), 2014 42<br />
Figure 14: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Clinical Trial Size (Participants), 2014 43<br />
Figure 15: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline Clinical Trial Duration (Months), 2014 44<br />
Figure 16: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Comparative Safety and Efficacy of Pipeline<br />
Products (Heat Map), 2014 50<br />
Figure 17: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Asia-Pacific, <strong>Market</strong> Size, 2013-<strong>2020</strong> 52<br />
Figure 18: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, Treatment Usage Pattern ('000), 2013-<strong>2020</strong> 53<br />
Figure 19: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, Annual Cost of Therapy ($), 2013-<strong>2020</strong> 54<br />
Figure 20: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, <strong>Market</strong> Size ($m), 2013-<strong>2020</strong> 55
Figure 21: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Australia, Treatment Usage Pattern ('000), 2013-<strong>2020</strong> 56<br />
Figure 22: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Australia, Annual Cost of Therapy ($'000), 2013-<strong>2020</strong> 57<br />
Figure 23: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Australia, <strong>Market</strong> Size ($m), 2013-<strong>2020</strong> 58<br />
Figure 24: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, China, Treatment Usage Pattern ('000), 2013-<strong>2020</strong> 59<br />
Figure 25: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, China, Annual Cost of Therapy, 2013-<strong>2020</strong> 59<br />
Figure 26: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, China, <strong>Market</strong> Size ($m), 2013-<strong>2020</strong> 60<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
Figure 27: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Japan, Treatment Usage Pattern ('000), 2013-<strong>2020</strong> 61<br />
Figure 28: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Japan, Annual Cost of Therapy ($'000), 2013-<strong>2020</strong> 62<br />
Figure 29: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Japan, <strong>Market</strong> Size ($m), 2013-<strong>2020</strong> 63<br />
Figure 30: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global Deals by Value, Year and Stage of Development,<br />
2006-2014 66<br />
Figure 31: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Deals by Phase, Molecule Type and Mechanism of<br />
Action, 2006-2014 67<br />
Figure 32: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Co-development Deals by Geography, 2006-2014<br />
68<br />
Figure 33: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Licensing Deals by Geography, 2006-2014 70<br />
Figure 34: GBI <strong>Research</strong> <strong>Market</strong> Forecasting Model 95<br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market research<br />
reports, helping them in the decision making process. We have a comprehensive collection of reports,<br />
covering over 40 key industries and a host of micro markets. In addition to over extensive database of<br />
reports, our experienced research coordinators also offer a host of ancillary services such as, research<br />
partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />
Contact:<br />
Michelle Thoras
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://chemicalmaterialsmarket.blogspot.in/
Change language